[Profound survival benefit with concurrent chemotherapy: insights from a Chinese phase III trial in older patients with esophageal cancer]

Strahlenther Onkol. 2022 May;198(5):500-502. doi: 10.1007/s00066-022-01921-6. Epub 2022 Mar 14.
[Article in German]
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Comment

MeSH terms

  • Aged
  • Chemoradiotherapy
  • China
  • Esophageal Neoplasms* / drug therapy
  • Humans